IBM’s Twin Headlines: A Historic Selloff Meets a $10 Billion Quantum Punt

IBM shares suffered a historic 25% drop after mainframe revenue fell 42%, but a modest recovery and $12.5B in AI bookings raise questions about a true rebound.

On July 14, IBM shareholders endured the single worst trading day in the company’s 115-year history. The stock cratered 25.2 percent, wiping out months of gains in a matter of hours. The trigger was a preliminary quarterly report that revealed a 42 percent collapse in mainframe revenue — a figure so jarring that management itself described it as an “infrastructure core meltdown.” Yet even as the dust settles, the shares have staged a modest recovery, climbing 8.21 percent from their 52-week low of €175.14 hit on July 23 to trade near €189.52. The question hanging over the stock is whether this is the beginning of a genuine rebound or just a pause before another leg lower.

The mainframe implosion was not a story of lost market share. Rather, corporate clients shifted capital toward AI-ready servers and storage solutions, seeking to hedge against anticipated price increases for memory chips. That reallocation pushed several high-margin mainframe and transaction-software deals past the quarter-end cutoff. Crucially, IBM has stood by its full-year free cash flow forecast, still expecting an increase of roughly $1 billion over the prior year — a signal that the company’s cash-generation engine remains intact despite the revenue miss.

But the damage to investor confidence was compounded by a separate, more existential narrative that emerged just weeks earlier. On June 2, IBM announced plans to invest more than $10 billion over the next five years in quantum computing — research, manufacturing capacity, partnerships, and acquisitions. CEO Arvind Krishna framed the commitment as a necessity, not an option: “The quantum era is no longer ahead of us; it has begun.” The company aims to deliver the world’s first large-scale, fault-tolerant quantum computer by 2029, and has earmarked an additional $1 billion for Anderon, a planned quantum wafer fab that will be matched by another $1 billion from the U.S. CHIPS program.

The timing of that announcement now looks deeply unfortunate. Barely a month later, the mainframe shock landed, forcing investors to reconcile two conflicting realities: a core business that had just demonstrated how badly it could miss its own targets, and a decade-long promise whose commercial payoff remains years away. One analyst estimate pegs the pure quantum business at roughly $65 per share — a valuation that far exceeds the actual commercial contracts the division has signed since 2017. That gap between narrative and realized revenue was brutally exposed when the software and mainframe businesses missed their own forecasts.

Not all the news was bad. IBM’s software segment grew 5 percent in the second quarter, with Red Hat accelerating 11 percent and the data business jumping 19 percent. Cumulative bookings in generative AI have reached $12.5 billion, a figure that undercuts the notion that IBM is falling behind in the AI race. Software now represents a much larger share of total revenue, and 80 percent of it is recurring, providing a more predictable earnings base. Internally, the company’s AI coding tool “Bob,” now used by 80,000 employees, is expected to boost the pre-tax margin by a full percentage point this year.

Technically, the stock looks oversold but not broken. The 14-day RSI sits at 36.3 — no longer in extreme oversold territory, but still far from overheated. The gap to the 200-day moving average of €233.55 remains a yawning 18.85 percent, a measure of how deep the correction has cut. The 50-day moving average of €228.63 is even further above the current price, at a 16.42 percent premium. Annualized 30-day volatility has surged to 85.10 percent, reflecting the nervousness that now pervades trading.

Analyst consensus still points to a price target of €215.67 from the primary source and €231.07 from the secondary, though the latter figure predates the full digestion of the guidance cut and partly reflects lingering faith in the long-term technology story — quantum included. Krishna has promised that IBM’s partners will demonstrate a genuine “quantum advantage” before the end of 2026, the first credible leap from lab curiosity to commercial tool. If that materializes, it would be the first tangible proof in years that the quantum bet is more than a slide in an investor presentation.

For now, IBM finds itself caught in a tension that defines much of the tech sector: companies are expected to fund future technologies — quantum, AI infrastructure, custom chips — precisely when their current businesses are stalling and capital is tightening. The market has already priced in the short-term disappointment. Whether it has also correctly discounted the multi-decade payoff horizon of the quantum wager is the debate that will shape the stock’s trajectory long after this earnings shock fades from the headlines.